

Going Global – 70% of Reuse with Structured Content

Accelerate your time-to-market

Chip Gettinger
VP Global Solutions Consulting

9 October 2024

Agenda



Single source of truth to ensure a neutral source is ready for submission to multiple agencies, such as EMA, FDA, etc.



Instantiation of data, automatic table data instantiation with the ability to know when data is updated.




Global content automating translation and localization




Informed Consent Form use case of managing reuse from a global template to a country and site templates

Adoption of structured content components



Unstructured Content



Structured Content

Why create documents with structured content components?

Single source of truth



Write once, reuse many times



Semantically rich and interoperable



Full audit trail – compliancy



Unify collaboration, accuracy



Output and translation automation


“The output Informed Consent would serve as the starting point of negotiations with sites. This activity has enormous value, including shortened submission timelines, reduced errors, and site friendliness.

Consistency and Quality: This system could solve many of our protocol amendment issues seen to date.”

Medical writer at a pharmaceutical company

Managing documents as structured components



A structured approach to content creation supports content reuse and data integration at scale, facilitates faster creation and review, reduces conflicts/variation, and diminishes the need for data integrity checks



Collaborative authoring / review & versioning
Ability to generate output in Word / PDF / XML etc.

Component reuse within Informed Consent Templates

Global ICF Elements	Global ICF Template	Country/Site ICF Template
Global Cover Page	Global Cover Page	Country ICF Template Cover Page
Summary of the Study	Summary of the Study	Summary of the Study
Are there any benefits to me...	Are there any benefits to me...	Are there any benefits to me...
What happens at Study Visits?	What happens at Study Visits?	What happens at Study Visits?
	Signature Page	Country Signature Page
	Optional consent for activities...	Optional consent for activities...
	Optional consent for Additional...	Optional consent for Additional...

-  Component reuse (as-is)
-  Component reuse (derivative)

Informed Consent – Data-Driven Documents

Global IC Elements reused to generate Country IC

Fonto

START INSERT TOOLS

COMPONENT V1 Draft

3. Summary of the Study

Dear Participant:

T COMPANY FULL NAME are conducting a study to confirm the efficacy of a new treatment, T TREATMENT X NAME, for T DISEASE. We are sending you this form so that you and your child or ward can understand the risks and benefits of participating.

COMPONENT V1 Draft

4. What Happens at Study Visits?

Your child/ward will have access to T TREATMENT X NAME for the duration of the study.

Study Treatment

Your child/ward will have a 00 in 000 chance of receiving T TREATMENT X NAME for the duration of the study.

Placebo

Your child/ward will have a 00 in 000 chance of receiving a placebo for the duration of the study.

Dosages vary and are included in the following table:

TABLE

Table 2 Dosages

Fonto

Document view Zoom Quality check (off) Preview Show changes Search

COMPONENT Locked by you V1 In review

2. Summary of the Study

Dear Participant:

State University are conducting a study to confirm the efficacy of a new treatment, Rivanin, for diabetes. We are sending you this form so that you and your child or ward can understand the risks and benefits of participating. This CCB

Subsection 7. Optional consent for Additional Research using your Coded Data or Samples

COMPONENT Locked by you V1 Draft

3. What Happens at Study Visits?

Your child/ward will have access to Rivanin for the duration of the study.

Study Treatment

Your child/ward will have a 00 in 000 chance of receiving Rivanin for the duration of the study.

Placebo

Your child/ward will have a 00 in 000 chance of receiving a placebo for the duration of the study.

Dosages vary and are included in the following table:

Powerful reuse reporting

Show reuse summary

Shared with

Search

Template name	Status	Date created	Last modified	Authors	Reviewers	Release note
ICF - Global IC Elements -V1	Draft	8/19/2024 - Mike Mina...	8/19/2024 - Mike Mina...		Sara Pawl...	No value
ICF - US ICF Template -V1	Draft	8/19/2024 - Mike Mina...	9/30/2024 - Chip Getti...		Sara Pawl...	No value

Cancel

benefits

COMPONENT

2

Shared in this document

V1 Draft

4.1

Are there any benefits to me if I decide to join the Study?

4.1 Are there any benefits to me if...

From country-focused IC administration to...

- Responsibility at country level
- Inconsistent processes
- Administrative burden on clinicians
- No reuse of content or translation

Higher cost, slower pace, less control



Structured Component Content +
Translation Management

- Global control
- Consistent processes
- Improved quality/reduced risk
- Minimize translation / lower costs

...Global Content and translation management

“It took me about five hours to redo the authoring of this section, considering all the tables and data content that is available. In contrast to this, usually, it would take me a minimum of 10 to 15 hours to complete the same work.”

Medical writer at a pharmaceutical company

“We release five new products to the market per year, and that number is growing. Per new drug application, our scientists spend 800 days on automatable work, i.e. collect, retype, change, insert and format content and data. We needed to speed up these processes and reduce the amount of costly manual work. That’s solved by Fonto IAP.”

Digital Transformation Program Lead at a pharmaceutical company

Thank you! Learn more

www.fontoxml.com/iap

Learn more on the advantages of structured content within pharmaceutical use cases

www.ebcont.com

Implementation and configuration partner



www.rws.com





RWS Holdings plc is a unique, world-leading provider of technology-enabled language, content and intellectual property services. Through content transformation and multilingual data analysis, our combination of AI-enabled technology and human expertise helps our clients to grow by ensuring they are understood anywhere, in any language.

Our purpose is unlocking global understanding. By combining cultural understanding, client understanding and technical understanding, our services and technology assist our clients to acquire and retain customers, deliver engaging user experiences, maintain compliance and gain actionable insights into their data and content.

Over the past 20 years we've been evolving our own AI solutions as well as helping clients to explore, build and use multilingual AI applications. With 45+ AI-related patents and more than 100 peer-reviewed papers, we have the experience and expertise to support clients on their AI journey.

We work with over 80% of the world's top 100 brands, more than three-quarters of Fortune's 20 'Most Admired Companies' and almost all of the top pharmaceutical companies, investment banks, law firms and patent filers. Our client base spans Europe, Asia Pacific, Africa and North and South America. Our 65+ global locations across five continents service clients in the automotive, chemical, financial, legal, medical, pharmaceutical, technology and telecommunications sectors.

Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).

For further information, please visit: www.rws.com.

© 2024 All rights reserved. Information contained herein is deemed confidential and the proprietary information of RWS Group*.

*RWS Group shall mean RWS Holdings plc for and on behalf of its affiliates and subsidiaries.